Merck's Q2 Earnings: Revenue And EPS Beat Helped By Strong Keytruda Sales, But Acquisition Costs Bites Into Annual Profit Forecast
Merck's Q2 Earnings: Revenue And EPS Beat Helped By Strong Keytruda Sales, But Acquisition Costs Bites Into Annual Profit Forecast
On Wednesday, Merck & Co Inc (NYSE:MRK) reported second-quarter sales of $16.1 billion, up 7% year-over-year, beating the consensus estimate of $15.84 billion. Excluding the impact of foreign exchange, sales increased 11%.
周三，默沙东公司（纽约证券交易所代码：MRK）公布第二季度销售额为161亿美元，同比增长7％，超过市场普遍预期的158.4亿美元。不包括外汇的影响，销售额增长了11％。
Merck reported adjusted EPS of $2.28, a shift from an EPS loss of $(2.06), beating the consensus of $2.15.
默沙东报告调整后的每股收益为2.28美元，较每股收益亏损2.06美元（2.06美元）有所变化，超过了市场普遍的2.15美元。
The pharmaceutical unit booked $14.41 billion in revenue, up 7% year over year. Growth in oncology, cardiovascular, and vaccines, partially offset by declines in diabetes and virology, drove the growth.
该制药部门的收入为144.1亿美元，同比增长7％。肿瘤学、心血管和疫苗的增长部分被糖尿病和病毒学的下降所抵消，推动了增长。
Also Read: Merck Gets Legal Victory As Appeals Court Dismisses Shingles Vaccine Some 1,200 Lawsuits.
另请阅读：上诉法院驳回了约1,200起带状疱疹疫苗诉讼，默沙东获得了法律胜利。
Merck's blockbuster cancer immunotherapy Keytruda generated $7.27 billion in revenue during the quarter, up 16% from the year-earlier period.
默克重磅癌症免疫疗法Keytruda在本季度创造了72.7亿美元的收入，比去年同期增长了16％。
Merck also reported a marginal increase of 1% in sales of Gardasil to $2.48 billion, a vaccine that prevents cancer from HPV, the most common sexually transmitted infection in the U.S. Growth was largely offset by lower sales in China.
默沙东还报告称，Gardasil的销售额小幅增长了1％，达到24.8亿美元。HPV是一种预防HPV（美国最常见的性传播感染）致癌的疫苗。增长在很大程度上被中国销售的下降所抵消。
The newly approved Winrevair (sotatercept) for adults with pulmonary arterial hypertension generated sales of $70 million.
新批准的用于成人肺动脉高压的Winrevair（sotatercept）的销售额为7,000万美元。
During the quarter, the FDA approved Merck's Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) to protect against 21 strains of bacteria to prevent a severe form of pneumococcal disease, as the first pneumococcal conjugate vaccine specifically designed to protect adults.
在本季度，美国食品和药物管理局批准了默克公司的Capvaxive（肺炎球菌21价偶联疫苗），以预防21种细菌菌株，以预防严重的肺炎球菌疾病，这是第一种专门为保护成年人而设计的肺炎球菌偶联疫苗。
Also, the company, with its partner Daiichi Sankyo (OTC:DSKYF) (OTC:DSNKY) received an FDA Complete Response Letter (CRL) for the Biologics License Application (BLA) seeking accelerated approval of patritumab deruxtecan (HER3-DXd) for a certain type lung cancer.
此外，该公司与其合作伙伴第一三共公司（场外交易代码：DSNKY）（场外交易代码：DSNKY）收到了美国食品药品管理局生物制剂许可申请（BLA）的完整回复信（CRL），要求加快批准用于特定类型肺癌的帕曲单抗德鲁斯特康（HER3-DxD）。
Guidance: Merck revised and narrowed its full-year 2024 forecasts.
指导：默沙东修订并缩小了其2024年全年预测。
The company expects 2024 sales of $63.4 billion—$64.4 billion, compared to previous guidance of $63.1 billion—$64.3 billion and the consensus of $64.34 billion.
该公司预计，2024年的销售额为634亿美元至644亿美元，而之前的预期为631亿美元至643亿美元，共识为643.4亿美元。
The U.S. pharma giant expects 2024 adjusted EPS of $7.94 to $8.04, compared to prior guidance of $8.53-$8.65 and consensus of $8.16.
这家美国制药巨头预计，2024年调整后的每股收益为7.94美元至8.04美元，而之前的预期为8.53-8.65美元，共识为8.16美元。
The outlook includes one-time charges of $0.77 per share For Harpoon and Eyebio acquisitions.
展望包括收购Harpoon和Eyebio的每股0.77美元的一次性费用。
Price Action: MRK stock is down 3.19% at $123.70 during the premarket session at last check Tuesday.
价格走势：在周二最后一次盘前交易中，MrK股价下跌3.19％，至123.70美元。
- Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants.
- 默沙东与赛诺菲/阿斯利康竞争，因为其呼吸道合胞病毒治疗药物在婴儿后期研究中达到了主要目标。
Photo Courtesy of Merck
照片由默沙东提供